160 related articles for article (PubMed ID: 20306217)
1. Combination therapy with dexamethasone and osteoprotegerin protects against arthritis-induced bone alterations in antigen-induced arthritis of the rat.
Oelzner P; Fleissner-Richter S; Bräuer R; Hein G; Wolf G; Neumann T
Inflamm Res; 2010 Sep; 59(9):731-41. PubMed ID: 20306217
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis.
Neumann T; Oelzner P; Petrow PK; Thoss K; Hein G; Stein G; Bräuer R
Inflamm Res; 2006 Jan; 55(1):32-9. PubMed ID: 16429254
[TBL] [Abstract][Full Text] [Related]
3. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.
Stolina M; Schett G; Dwyer D; Vonderfecht S; Middleton S; Duryea D; Pacheco E; Van G; Bolon B; Feige U; Zack D; Kostenuik P
Arthritis Res Ther; 2009; 11(6):R187. PubMed ID: 20003323
[TBL] [Abstract][Full Text] [Related]
4. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines.
Naidu VG; Dinesh Babu KR; Thwin MM; Satish RL; Kumar PV; Gopalakrishnakone P
Chem Biol Interact; 2013 Apr; 203(2):467-79. PubMed ID: 23333834
[TBL] [Abstract][Full Text] [Related]
5. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis.
Ho TY; Santora K; Chen JC; Frankshun AL; Bagnell CA
Bone; 2011 Jun; 48(6):1346-53. PubMed ID: 21419242
[TBL] [Abstract][Full Text] [Related]
6. Total glucosides of paeony prevents juxta-articular bone loss in experimental arthritis.
Wei CC; You FT; Mei LY; Jian S; Qiang CY
BMC Complement Altern Med; 2013 Jul; 13():186. PubMed ID: 23870279
[TBL] [Abstract][Full Text] [Related]
7. 1,25-Dihydroxyvitamin D3 prevents bone loss of the secondary spongiosa in arthritic rats by an increase of bone formation and mineralization and inhibition of bone resorption.
Oelzner P; Petrow PK; Wolf G; Bräuer R
BMC Musculoskelet Disord; 2014 Oct; 15():345. PubMed ID: 25315028
[TBL] [Abstract][Full Text] [Related]
8. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
[TBL] [Abstract][Full Text] [Related]
9. Periarticular bone alterations in chronic antigen-induced arthritis: free and liposome-encapsulated clodronate prevent loss of bone mass in the secondary spongiosa.
Oelzner P; Bräuer R; Henzgen S; Thoss K; Wünsche B; Hersmann G; Abendroth K; Kinne RW
Clin Immunol; 1999 Jan; 90(1):79-88. PubMed ID: 9884355
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
Swanson C; Lorentzon M; Conaway HH; Lerner UH
Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
[TBL] [Abstract][Full Text] [Related]
11. Boldine isolated from Litsea cubeba inhibits bone resorption by suppressing the osteoclast differentiation in collagen-induced arthritis.
Zhao H; Xu H; Qiao S; Lu C; Wang G; Liu M; Guo B; Tan Y; Ju D; Xiao C
Int Immunopharmacol; 2017 Oct; 51():114-123. PubMed ID: 28826044
[TBL] [Abstract][Full Text] [Related]
12. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models.
Schett G; Middleton S; Bolon B; Stolina M; Brown H; Zhu L; Pretorius J; Zack DJ; Kostenuik P; Feige U
Arthritis Rheum; 2005 May; 52(5):1604-11. PubMed ID: 15880601
[TBL] [Abstract][Full Text] [Related]
13. Total Saponin from Anemone flaccida Fr. Schmidt Prevents Bone Destruction in Experimental Rheumatoid Arthritis via Inhibiting Osteoclastogenesis.
Liu C; Yang Y; Sun D; Wang C; Wang H; Jia S; Liu L; Lin N
Rejuvenation Res; 2015 Dec; 18(6):528-42. PubMed ID: 26418168
[TBL] [Abstract][Full Text] [Related]
14. Anti-rheumatoid arthritis effects of iridoid glucosides from Lamiophlomis rotata (Benth.) kudo on adjuvant-induced arthritis in rats by OPG/RANKL/NF-κB signaling pathways.
Zhao X; Jiang S; Dong Q; Dang J; Liu Z; Han H; Tao Y; Yue H
J Ethnopharmacol; 2021 Feb; 266():113402. PubMed ID: 32980481
[TBL] [Abstract][Full Text] [Related]
15. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis.
Stolina M; Adamu S; Ominsky M; Dwyer D; Asuncion F; Geng Z; Middleton S; Brown H; Pretorius J; Schett G; Bolon B; Feige U; Zack D; Kostenuik PJ
J Bone Miner Res; 2005 Oct; 20(10):1756-65. PubMed ID: 16160733
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of total flavonoids of Astragalus against adjuvant-induced arthritis in rats by regulating OPG/RANKL/NF-κB pathway.
Liu XY; Xu L; Wang Y; Li JX; Zhang Y; Zhang C; Wang SS; Zhang XM
Int Immunopharmacol; 2017 Mar; 44():105-114. PubMed ID: 28092862
[TBL] [Abstract][Full Text] [Related]
18. High-dose clodronate therapy prevents joint destruction in chronic antigen-induced arthritis of the rat but inhibits bone formation at the axial skeleton.
Oelzner P; Kunze A; Henzgen S; Thoss K; Hein G; Stein G; Bräuer R
Inflamm Res; 2000 Aug; 49(8):424-33. PubMed ID: 11028760
[TBL] [Abstract][Full Text] [Related]
19. The peroxisome proliferator-activated receptor γ agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway.
Koufany M; Chappard D; Netter P; Bastien C; Weryha G; Jouzeau JY; Moulin D
Arthritis Rheum; 2013 Dec; 65(12):3084-95. PubMed ID: 23982996
[TBL] [Abstract][Full Text] [Related]
20. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance.
Lubberts E; van den Bersselaar L; Oppers-Walgreen B; Schwarzenberger P; Coenen-de Roo CJ; Kolls JK; Joosten LA; van den Berg WB
J Immunol; 2003 Mar; 170(5):2655-62. PubMed ID: 12594294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
